|Bid||1.1200 x 4000|
|Ask||1.1900 x 1000|
|Day's Range||1.1000 - 1.2500|
|52 Week Range||1.0300 - 5.9900|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2018 - Feb 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.00|
Bioblast Pharma Ltd. (ORPN) is providing an update on business development activities as well as notice of an organization change that affects members of the board and management. As previously announced, the Company is seeking a commercial partner for its investigational proprietary intravenous (IV) form of trehalose 90 mg/mL solution (trehalose), which has been studied in humans with ocular pharyngeal muscular dystrophy (OPMD) and Spinocerebellar Ataxia Type 3 (SCA3). Although no partnership or other arrangement has been concluded, the Company is working diligently to find such a partner, as well as to enter into a merger agreement with a third party.
Today, I will be analyzing Bioblast Pharma Ltd’s (NASDAQ:ORPN) recent ownership structure, an important but not-so-popular subject among individual investors. When it comes to ownership structure of a company, theRead More...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! athenahealth, Inc (NASDAQ: ATHN ) stock was trading ...
If you are looking to invest in Bioblast Pharma Ltd’s (NASDAQ:ORPN), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...
I am going to take a deep dive into Bioblast Pharma Ltd’s (NASDAQ:ORPN) most recent ownership structure, not a frequent subject of discussion among individual investors. A company’s ownership structureRead More...
In case you missed it, here are some of Benzinga's top stories from Wednesday, Jan. 17, 2018. Blockchain ETFs’ Inaugural Trading Session Wayne Duggan breaks down the arrival of new ETFs - Reality Shares ...
Bioblast Pharma Ltd (NASDAQ:ORPN), a USD$7.59M small-cap, operates in the healthcare industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population,Read More...
The Tel Aviv, Israel-based company said it had a loss of 32 cents per share. The company's shares closed at $2.27. A year ago, they were trading at $7.15. _____ This story was generated by Automated Insights ...